Key Highlights
- $20 million Series B extension financing to propel the commercial and clinical activities of the BEAR Implant.
- The BEAR Implant offers a revolutionary shift in ACL tear treatment, promoting natural healing without grafts.
- Major partnerships with MLSPA, SV Health Investors, and Aperture Venture Partners, underscoring strong support from the sports and investment communities.
Source: Business Wire
Notable Quotes
- “This financing will enable continued growth of our commercial organization in the U.S., as well as support clinical initiatives like the Bridge Registry to provide important data on real-world patient outcomes,” – Patrick McBrayer, President and CEO at Miach Orthopaedics
- “Miach’s ability to continue to attract significant investment is a testament to the management team’s leadership in driving rapid adoption of the BEAR Implant across the U.S.,” – Joyce Erony, Managing Partner at Amzak Health
SoHC's Take
The BEAR Implant from Miach Orthopaedics is setting a new horizon in the treatment of ACL injuries, marking a departure from traditional reconstruction methods to a more natural restoration process. This innovative approach, backed by substantial Series B extension financing, highlights the potential of the BEAR Implant to redefine standard care for ACL tears. With its application already benefiting a diverse range of athletes, from professionals to enthusiastic amateurs, the BEAR Implant represents a significant advancement in orthopedic medicine. The involvement of leading sports associations and healthcare investors not only underscores the implant’s potential impact on athlete care but also its broader implications for advancing medical technology in connective tissue restoration. As the BEAR Implant continues to gain traction, its role in promoting faster, more natural healing processes presents an exciting future for ACL injury treatment.
